251 related articles for article (PubMed ID: 27250896)
1. Novel agents in second-line therapy for EGFR wild-type Advanced Non-Small-Cell Lung Cancer.
El Amarti L; Elghissassi I; Layachi M; Mrabti H; Errihani H
Gulf J Oncolog; 2016 May; 1(21):84-8. PubMed ID: 27250896
[TBL] [Abstract][Full Text] [Related]
2. From 2000 to 2016: Which Second-Line Treatment in Advanced Non-Small Cell Lung Cancer?
D'Argento E; Rossi S; Schinzari G; Strippoli A; Basso M; Cassano A; Barone C
Curr Treat Options Oncol; 2016 Dec; 17(12):59. PubMed ID: 27766545
[TBL] [Abstract][Full Text] [Related]
3. Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer.
Chen YM
J Chin Med Assoc; 2013 May; 76(5):249-57. PubMed ID: 23683257
[TBL] [Abstract][Full Text] [Related]
4. Impact of Epidermal Growth Factor Receptor Mutation on Clinical Outcomes of Nintedanib Plus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer from the Korean Named Patient Program.
Hong SH; An HJ; Kim K; Lee SS; Lee YG; Yuh YJ; Park IC; Chae YS; Jang TW; Kang JH
Oncology; 2019; 96(1):51-58. PubMed ID: 30368503
[TBL] [Abstract][Full Text] [Related]
5. Second-line treatment for advanced NSCLC without actionable mutations: is immunotherapy the 'panacea' for all patients?
Morabito A
BMC Med; 2018 Feb; 16(1):24. PubMed ID: 29448944
[TBL] [Abstract][Full Text] [Related]
6. Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC).
Kumarakulasinghe NB; van Zanwijk N; Soo RA
Respirology; 2015 Apr; 20(3):370-8. PubMed ID: 25689095
[TBL] [Abstract][Full Text] [Related]
7. Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung.
Goss GD; Spaans JN
Oncologist; 2016 Feb; 21(2):205-13. PubMed ID: 26768483
[TBL] [Abstract][Full Text] [Related]
8. The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer.
Stinchcombe TE
Curr Treat Options Oncol; 2016 Apr; 17(4):18. PubMed ID: 26961971
[TBL] [Abstract][Full Text] [Related]
9. Extending survival of stage IV non-small cell lung cancer.
Carnio S; Novello S; Mele T; Levra MG; Scagliotti GV
Semin Oncol; 2014 Feb; 41(1):69-92. PubMed ID: 24565582
[TBL] [Abstract][Full Text] [Related]
10. [The evolution of the treatment of advanced NSCLC.].
Morabito A
Recenti Prog Med; 2016 Oct; 107(10):510-514. PubMed ID: 27782226
[TBL] [Abstract][Full Text] [Related]
11. Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance.
Jotte RM; Spigel DR
Cancer Med; 2015 Nov; 4(11):1621-32. PubMed ID: 26310719
[TBL] [Abstract][Full Text] [Related]
12. Management and future directions in non-small cell lung cancer with known activating mutations.
Gerber DE; Gandhi L; Costa DB
Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trials.
Zhao N; Zhang XC; Yan HH; Yang JJ; Wu YL
Lung Cancer; 2014 Jul; 85(1):66-73. PubMed ID: 24780111
[TBL] [Abstract][Full Text] [Related]
14. EGFR Mutation Impact on Definitive Concurrent Chemoradiation Therapy for Inoperable Stage III Adenocarcinoma.
Tanaka K; Hida T; Oya Y; Oguri T; Yoshida T; Shimizu J; Horio Y; Hata A; Kaji R; Fujita S; Sekido Y; Kodaira T; Kokubo M; Katakami N; Yatabe Y
J Thorac Oncol; 2015 Dec; 10(12):1720-5. PubMed ID: 26743855
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes of thoracic radiotherapy for locally advanced NSCLC with EGFR mutations or EML4-ALK rearrangement.
Hayashi H; Okamoto I; Kimura H; Sakai K; Nishimura Y; Nishio K; Nakagawa K
Anticancer Res; 2012 Oct; 32(10):4533-7. PubMed ID: 23060582
[TBL] [Abstract][Full Text] [Related]
16. Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors.
Juchum M; Günther M; Laufer SA
Drug Resist Updat; 2015 May; 20():12-28. PubMed ID: 26021435
[TBL] [Abstract][Full Text] [Related]
17. The safety of second-line treatment options for non-small cell lung cancer.
Rossi A; Maione P; Santabarbara G; Sacco PC; Casaluce F; Sgambato A; Barzelloni ML; Palazzolo G; Gridelli C
Expert Opin Drug Saf; 2017 Apr; 16(4):471-479. PubMed ID: 28276858
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?
Remon J; Hendriks LE; Cabrera C; Reguart N; Besse B
Cancer Treat Rev; 2018 Dec; 71():47-58. PubMed ID: 30359792
[TBL] [Abstract][Full Text] [Related]
19. Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice - results from the ElderTac study.
Brueckl WM; Achenbach HJ; Ficker JH; Schuette W
BMC Cancer; 2018 Mar; 18(1):333. PubMed ID: 29587656
[TBL] [Abstract][Full Text] [Related]
20. BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational study.
Vavalà T; Follador A; Tiseo M; Galetta D; Morabito A; Di Maio M; Martelli O; Caffo O; Piovano PL; Cortinovis D; Zilembo N; Casartelli C; Banna GL; Ardizzoia A; Barzelloni ML; Bearz A; Genestreti G; Mucciarini C; Filipazzi V; Menis J; Rizzo E; Barbieri F; Rijavec E; Cecere F; Bria E; Spitaleri G; Rossi A; Novello S
Lung Cancer; 2016 May; 95():73-81. PubMed ID: 27040855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
